Viloria-Petit A - Search Results

1

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Viloria-Petit A, et al. Cancer Res. 2001 Jul 1;61(13):5090-101. Cancer Res. 2001. PMID: 11431346

2

Establishing a link between oncogenes and tumor angiogenesis.

Kerbel RS, Viloria-Petit A, Okada F, Rak J. Kerbel RS, et al. Mol Med. 1998 May;4(5):286-95. Mol Med. 1998. PMID: 9642680 Free PMC article. Review.

3

Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts.

Rak J, Mitsuhashi Y, Sheehan C, Tamir A, Viloria-Petit A, Filmus J, Mansour SJ, Ahn NG, Kerbel RS. Rak J, et al. Cancer Res. 2000 Jan 15;60(2):490-8. Cancer Res. 2000. PMID: 10667605

4

'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples.

Kerbel RS, Viloria-Petit A, Klement G, Rak J. Kerbel RS, et al. Eur J Cancer. 2000 Jun;36(10):1248-57. doi: 10.1016/s0959-8049(00)00092-7. Eur J Cancer. 2000. PMID: 10882863 Review.

5

Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.

López-Ocejo O, Viloria-Petit A, Bequet-Romero M, Mukhopadhyay D, Rak J, Kerbel RS. López-Ocejo O, et al. Oncogene. 2000 Sep 21;19(40):4611-20. doi: 10.1038/sj.onc.1203817. Oncogene. 2000. PMID: 11030150

6

Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches.

Kerbel RS, Yu J, Tran J, Man S, Viloria-Petit A, Klement G, Coomber BL, Rak J. Kerbel RS, et al. Cancer Metastasis Rev. 2001;20(1-2):79-86. doi: 10.1023/a:1013172910858. Cancer Metastasis Rev. 2001. PMID: 11831651 Review.

7

Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody.

Crombet-Ramos T, Rak J, Pérez R, Viloria-Petit A. Crombet-Ramos T, et al. Int J Cancer. 2002 Oct 20;101(6):567-75. doi: 10.1002/ijc.10647. Int J Cancer. 2002. PMID: 12237899

8

Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors.

Viloria-Petit A, Miquerol L, Yu JL, Gertsenstein M, Sheehan C, May L, Henkin J, Lobe C, Nagy A, Kerbel RS, Rak J. Viloria-Petit A, et al. EMBO J. 2003 Aug 15;22(16):4091-102. doi: 10.1093/emboj/cdg408. EMBO J. 2003. PMID: 12912908 Free PMC article.

9

Versican/PG-M G3 domain promotes tumor growth and angiogenesis.

Zheng PS, Wen J, Ang LC, Sheng W, Viloria-Petit A, Wang Y, Wu Y, Kerbel RS, Yang BB. Zheng PS, et al. FASEB J. 2004 Apr;18(6):754-6. doi: 10.1096/fj.03-0545fje. Epub 2004 Feb 6. FASEB J. 2004. PMID: 14766798

10

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies.

Viloria-Petit AM, Kerbel RS. Viloria-Petit AM, et al. Int J Radiat Oncol Biol Phys. 2004 Mar 1;58(3):914-26. doi: 10.1016/j.ijrobp.2003.09.091. Int J Radiat Oncol Biol Phys. 2004. PMID: 14967451 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

45 results

Search Page

Filters